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BRCA1 Is Associated with a Human SWI/SNF-Related
Complex: Linking Chromatin Remodeling
to Breast Cancer
Verma, 1996; Monteiro et al., 1996). Moreover, BRCA1
was not only shown to function as a coactivator for
p53-mediated transcription, but also its overexpression
resulted in enhancement of p53-independent gene ex-
pression (Somasundaram et al., 1997; Ouchi et al., 1998).
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To elucidate the molecular mechanism by which
BRCA1 induces such a broad range of effects, we iso-
lated the predominant BRCA1-containing complex fromSummary
HeLa cells and identified its components by mass spec-
trometric peptide sequencing. Here we show that
Germline mutations in the tumor suppressor gene, BRCA1 is a component of a human SWI/SNF-related
BRCA1, predispose individuals to breast and ovarian complex. We have isolated the BRCA1 complex using
cancers. Using a combination of affinity- and conven- three independent approaches, resulting in a similar
tional chromatographic techniques, we have isolated polypeptide composition. These data not only provide
a predominant form of a multiprotein BRCA1-contain- a clear connection between BRCA1 and transcriptional
ing complex from human cells displaying chromatin- regulatory machinery, but also point to the other compo-
remodeling activity. Mass spectrometric sequencing of nents of the SWI/SNF complex as potential genes whose
components of this complex indicated that BRCA1 is mutations may result in breast and ovarian cancers.
associated with a SWI/SNF-related complex. We show
that BRCA1 can directly interact with the BRG1 subunit Results
of the SWI/SNF complex. Moreover, p53-mediated
stimulation of transcription by BRCA1 was completely Affinity-Purification of a BRCA1 Complex
abrogated by either a dominant-negative mutant of To determine the polypeptide composition of endoge-
BRG1 or the cancer-causing deletion in exon 11 of nous BRCA1-containing complex(es), HeLa nuclear ex-
BRCA1. These findings reveal a direct function for tract was chromatographed sequentially to enrich for
BRCA1 in transcriptional control through modulation BRCA1-containing complex(es) (Figure 1A). Analysis of
of chromatin structure. these fractions by gel filtration chromatography re-
vealed that BRCA1 is a component of a 2 MDa complex
(data not shown). To purify this complex, DEAE-Sepha-Introduction
cel fractions were subjected to affinity-purification using
polyclonal anti-BRCA1 antibodies. Polypeptides specifi-BRCA1 is a tumor suppressor gene that is linked to
cally eluted from the BRCA1 affinity matrix (Figure 1B)familial breast and ovarian cancers (Hall et al., 1990;
were sequenced by ion trap tandem mass spectrometry.Miki et al., 1994). The BRCA1 gene encodes a protein
Twenty-six tryptic peptide sequences confirmed theof 1863 amino acids without extensive homology to
identity of the 210 kDa polypeptide as BRCA1, indicatingother proteins in the database (Miki et al., 1994). The
that the purification was specific. However, the yieldsprimary sequence contains two motifs characteristic of
for the BRCA1 protein were variable in different prepara-transcription factors (Miki et al., 1994). These include
tions, as it could not be efficiently eluted from the affinitya RING-finger motif and an acidic carboxyl terminus.
matrix.Fusions of this carboxyl terminus to the DNA binding
domain of the GAL4 protein endows the chimeric protein
with transcriptional stimulatory activity (Chapman and BRCA1 Is a Component of Human SWI/SNF
Chromatin Remodeling Complex
Five peptide sequences identified the 180 kDa polypep-k To whom correspondence should be addressed (e-mail: shiekhattar@
wistar.upenn.edu). tide as human BRG1 protein. The 60 kDa polypeptide
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of BRCA1 with SWI/SNF complex, we analyzed the
BRCA1-affinity eluate in a mononucleosome digestion
assay. As Figure 1C indicates the affinity-purified
BRCA1 complex displayed chromatin remodeling activ-
ity by altering the ATP-dependent DNase I cleavage
of mononucleosomes to a pattern which more closely
resembled that of naked DNA. These results revealed a
physical association of the BRCA1 protein with the SWI/
SNF chromatin remodeling complex.
BRCA1-SWI/SNF Is a Predominant Human
BRCA1-Containing Complex
BRCA1 is reported to be a component of number of
different complexes (Scully et al., 1997a, 1999; Zhong
et al., 1999). To confirm the association of BRCA1 and
the SWI/SNF-related complexes and to gain some in-
sight into the number of BRCA1-containing complexes,
we purified the BRCA1 complex(es) to near homogeneity
by fractionating HeLa nuclear extract following the
scheme shown in Figure 2A. Western blot analysis of
column fractions throughout the entire purification steps
revealed the precise coelution of BRCA1 and the com-
ponents of the SWI/SNF complex (Figures 2B and 2C).
It is noteworthy that only a single peak of BRCA1 immu-
noreactivity was detected on every column, and this
peak coeluted with components of the SWI/SNF com-
plex (Figures 2B, 2C, and 3B). These results indicate that
BRCA1-SWI/SNF represent the predominant BRCA1-
containing complex in HeLa nuclear extract.
Similar to the affinity-purified BRCA1-SWI/SNF com-
plex, the conventionally purified complex displayed mono-
nucleosome disruption activity (Figure 2C). Figure 2D
displays the polypeptide composition of the BRCA1-
Figure 1. Affinity Purification of the BRCA1-SWI/SNF Complex SWI/SNF complex from the last chromatographic step.
(A) Purification scheme. HeLa nuclear extract was fractionated using In addition to the previously described components of
phosphocellulose (P11) chromatography. The 0.5 M KCl elution was the SWI/SNF complex, the BRCA1-SWI/SNF complex
concentrated on a DEAE-Sephacel column and further purified using contains additional unidentified components (Figure 2D).
an anti-BRCA1 antibody column (a-BRCA1). The bound proteins
were washed with buffer containing 1 M KCl and eluted using either
a peptide corresponding to the C20 epitope (4 mg/ml) or 0.2 M BRCA1-SWI/SNF Is a Novel
glycine, pH 2.5. BRCA1-Containing Complex(B) Polypeptide composition of the affinity-purified BRCA1-SWI/SNF
We asked whether the additional components of thecomplex. Affinity-purified BRCA1-SWI/SNF was analyzed by SDS-
BRCA1-SWI/SNF complex represent the polypeptidesPAGE followed by silver staining or Western blot analysis using
previously shown to be associated with BRCA1. BRCA1antibodies delineated to the right of the figure. a-control represents
was reported to be a component of the RNAPII holoen-the control protein A eluate. Molecular weight markers are shown
to the left of the figure. zyme complex (Scully et al., 1997a). Using a reconstitu-
(C) Mononucleosome disruption activity of the anti-BRCA1 affinity ted transcription system, we tested whether the BRCA1-
eluate. BRCA1-SWI/SNF (10 ml) was incubated with mononucleo- SWI/SNF complex displays RNAPII transcription activity
somes in the presence or absence of ATP followed by digestion of (Figure 3A). Analysis of BRCA1-SWI/SNF complex in
the mononucleosomes with DNase I. Control lanes 1 and 2 represent such an assay revealed the absence of RNAPII activityfree DNA and mononucleosome DNA. The arrows to the right denote
(compare lanes 2 and 5). Indeed, Western blot analysisthe changes in nucleosome digestion pattern due to BRCA1-SWI/
of the earlier chromatographic steps (Phenyl Sepharose)SNF activity.
indicated that BRCA1 and RNAPII have different elution
profiles (Figure 3B). Thus, the BRCA1-SWI/SNF complex
is not a component of a human RNA polymerase IIcontained three peptide sequences corresponding to
BAF60b. BRG1 and BAF60 were reported to be compo- complex.
BRCA1 was also shown to be in a stable complexnents of the multiprotein human chromatin remodeling
complex, SWI/SNF (Wang et al., 1996a, 1996b). Western with the human Rad50-hMre11-p95 complex (Zhong et
al., 1999). Although some components of the RAD50/blot analysis of the BRCA1 affinity eluate revealed
the presence of other SWI/SNF components (SNF5, Mre11/p95 complexes copurified with BRCA1 on earlier
steps of the purification, Western blot analysis of theBAF155, BAF170; Figure 1B). The SWI/SNF complex is
reported to display chromatin remodeling activity as Superose 6 column fractions indicated that RAD50/
Mre11/p95 are components of a larger complex (Figuremeasured by changes in the DNase I digestion pattern
of mononucleosomes in an ATP-dependent manner 3C). In addition, the BRCA1-SWI/SNF complex was de-
void of the BRCA2 protein (data not shown). Taken to-(Cote et al., 1994; Wang et al., 1996a; Phelan et al., 1999;
Bochar et al., 2000). To further establish the association gether, these results indicate that BRCA1-SWI/SNF is
BRCA1 Is a Component of a Chromatin Remodeling Complex
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Figure 2. Conventional Purification of BRCA1-
SWI/SNF Complex
(A) Purification scheme. HeLa nuclear extract
was fractionated by chromatography as de-
scribed in Experimental Procedures. The hor-
izontal and diagonal lines indicate stepwise
and gradient elution, respectively. Concen-
trations are given in molars.
(B) Western blot analysis of the Mono Q frac-
tions (15 ml) using antibodies shown to the
right of the figure.
(C) Western blot analysis and mononucleo-
some disruption assay of Superose 6 frac-
tions (15 ml). Input (I) is the BRCA1 pool from
the Mono Q column. The arrow at the bottom
denotes the elution position of thyroglobulin.
(D) BRCA1-SWI/SNF (15 ml) from the Su-
perose 6 column was separated by SDS-
PAGE (4%±12%) and visualized by silver
staining. Molecular masses of marker pro-
teins are indicated at the left. Protein assign-
ments were based on Western blot analysis
and by comparison to SWI/SNF complexes
affinity-purified using antibodies to other
SWI/SNF components (Wang et al., 1996a,
1996b).
a different complex than that of previously described BRCA1 Directly Interacts with BRG1
BRCA1-containing complexes. To determine which subunit of SWI/SNF can mediate
the interaction with BRCA1, Flag-BRG1 or the trimeric
Flag-SNF5/BAF155/BAF170 complex was produced inAffinity-Purified Human SWI/SNF Contains BRCA1
insect cells and purified to homogeneity (Figure 5A).To further examine the association of the SWI/SNF com-
Full-length his-tagged BRCA1 was also produced in in-plex with the BRCA1 protein, we purified SWI/SNF com-
sect cells and purified through a nickel column (Figureplex(es) from Ini-1-11 cells (Phelan et al., 1999). This
5A). The Flag-BRG1 or Flag-SNF5/BAF155/BAF170 wasHeLa-derived cell line expresses Flag-SNF5, a Flag-
then incubated with his-BRCA1 and the protein mix wastagged component of SWI/SNF complex. SNF5 is re-
then purified through a Flag affinity column. Bound pro-ported to be a core component of a number of SWI/
teins were eluted using Flag peptide and analyzed bySNF complexes in mammalian cells (Wang et al., 1996a,
Western blotting using anti-BRCA1, anti-BRG1, and1996b). Nuclear extract from Ini-1-11 cells or untagged
anti-SNF5 antibodies. As Figure 5B indicates, BRG1 canHeLa cells was affinity purified using anti-Flag antibod-
directly interact with BRCA1 while the trimeric complexies followed by elution of the bound material with Flag
of SNF5/BAF170/BAF155 cannot mediate the interac-peptide (Figure 4A). Western blot analysis of the affinity
tion with BRCA1. Addition of the trimeric complex toeluates revealed the specific association of BRCA1 with
the BRG1/BRCA1 reaction resulted in a slight increasethe tagged SWI/SNF complexes (Figure 4B). Further
in the recovery of BRCA1 and BRG1. These results dem-fractionation of the Flag-affinity eluate by Superose 6 gel
onstrate a direct interaction between the BRCA1 andfiltration and Western blot analysis of column fractions
BRG1 proteins. Similar results were obtained when his-demonstrated the association of BRCA1 with a 2 MDa
BRCA1 and Flag-BRG1 were coexpressed in insect cellsSWI/SNF complex (Figure 4C). It is noteworthy, that SWI/
and the BRG1/BRCA1 complex was purified using anSNF complex(es) purified from tagged Ini-1-11 cells dis-
anti-Flag affinity column (data not shown).played a higher levels of core-SWI/SNF components to
To determine which domain of BRCA1 interacts withthat of BRCA1, indicating that a portion of SWI/SNF
complexes contain BRCA1. BRG1, we performed protein±protein interaction studies
Cell
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Figure 3. BRCA1-SWI/SNF Does Not Contain RNAPII or Compo-
nents of the RAD50 Complex
(A) BRCA1-SWI/SNF lacks detectable RNAPII activity. Transcription
assays were reconstituted with rTBP (15 ng), rTFIIB (15 ng), rTFIIF
(20 ng), rTFIIE (20 ng), TFIIH (50 ng) in the presence or absence of
50 ng (13) of RNAPII or 50 ng (13) of BRCA1-SWI/SNF.
(B) RNAPII fails to coelute during chromatography on Phenyl Sepha-
rose. Western blot analysis of Phenyl Sepharose fractions (15 ml)
using antibodies indicated to the right of the figure. The input and
flowthrough are labeled I and FT, respectively.
(C) RAD50 and MRE11 fail to coelute during Superose 6 chromatog- Figure 4. Affinity-Purification of Human SWI/SNF Complex
raphy. Western blot analysis of Superose 6 gel filtration, the last (A) Purification scheme. Nuclear extract from Ini-1-11 or untagged
step of chromatography as shown in (Figure 2A), using antibodies HeLa cells was fractionated using an anti-Flag M2 affinity column.
indicated to the right of the figure. The arrow at the bottom denotes Bound proteins were further analyzed by chromatography on a Su-
the elution position of thyroglobulin. The void was deduced from perose 6 gel filtration column.
manufacturer's recommendation. (B) Western blot analysis of the anti-Flag affinity eluates (15 ml) using
antibodies shown to the right of the figure.
(C) Western blot analysis of the Superose 6 fractions (15 ml) using
antibodies shown to the right of the figure. The arrow at the bottomusing GST-BRCA1 constructs spanning the open read-
denotes the elution position of thyroglobulin. The void was deduceding frame (Figure 5C; Scully et al., 1997b). This analysis
from the manufacturer's recommendation.revealed a specific interaction of BRG1 with a fragment
of BRCA1 spanning the amino acids 260±553 encoded
within exon 11 (Figure 5D). (Figure 6A). This action of BRCA1 was specific as neither
the mutant BRCA1 lacking exon 11 nor transfection of
BRCA1 in the absence of p53 displayed a transcriptionBRCA1 Transcriptional Coactivation Is Mediated
through the SWI/SNF Complex stimulatory activity (Figure 6A).
To examine whether the BRCA1-dependent stimula-We next addressed the functional consequence of
BRCA1 association with the SWI/SNF complex. BRG1 tion of transcription is mediated through the SWI/SNF
complex, we tested the effect of increasing concentra-contains a DNA-dependent ATPase activity that is an
essential component of the SWI/SNF chromatin remod- tions of mutant or wild-type BRG1 on BRCA1-dependent
transcription. While addition of varying concentrationseling activity (Khavari et al., 1993). We reasoned that
since BRCA1 is associated with the SWI/SNF complex, (0.5±4 mg) of mutant BRG1 completely abrogated the
BRCA1-mediated transcription, only higher concentra-overexpression of the dominant-negative ATPase mu-
tant of BRG1 (K783R; Khavari et al., 1993), should func- tions of wild-type BRG1 (2±4 mg) displayed an inhibitory
effect (Figure 6B). This may be due to squelching oftionally interfere with the BRCA1-mediated transcription
activity. Consistent with a previous report (Ouchi et al., transcription by higher concentrations of BRG1. More-
over, cotransfection of the mutant BRG1 (5 mg) did not1998), transient transfection of BRCA1 resulted in a ro-
bust (3-fold) stimulation of p53-dependent transcription effect the TAT (HIV transactivator)-mediated stimulation of
BRCA1 Is a Component of a Chromatin Remodeling Complex
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Figure 5. BRCA1 Directly Interacts with BRG1
(A) SDS-PAGE (6%) followed by Coomassie
blue staining of purified recombinant Flag-
tagged BRG1, BAF170, BAF155, Flag-tagged
SNF5, and his-tagged BRCA1. (B) Recombi-
nant proteins denoted on the top of the figure
were incubated together according to the
protocol outlined in Experimental Procedures.
Following purification using an anti-Flag M2
affinity column, samples were subjected to
Western blotting analysis using antibodies in-
dicated to the right of the figure. NE repre-
sents HeLa nuclear extract (10 ml). (C) SDS-
PAGE followed by Coomassie blue staining
of purified recombinant GST-BRCA1 fusion
proteins synthesized as described in Experi-
mental Procedures. (D) Recombinant GST-
BRCA1 fusion proteins denoted on the top of
the figure were incubated with recombinant
BRG1 as outlined in Experimental Proce-
dures. Following elution with glutathione,
samples were subjected to Western blotting
analysis using anti-BRG1 antibodies.
transcription and only slightly reduced the TAX (HTLV-I 1999) complexes. Although we show that the BRCA1-
SWI/SNF complex is devoid of these polypeptides, wetransactivator)-mediated transcription (Figure 6C).
We extended this analysis by examining the role of cannot rule out the possibility that such complexes may
functionally interact with the BRCA1-SWI/SNF complex.the BRCA1-SWI/SNF complex in the activation of en-
dogenous p53-reponsive promoters. This analysis re- Such interactions are possible once BRCA1-SWI/SNF
complex is recruited during the process of transcriptionvealed a pronounced p53-dependent stimulation of the
p21 and p53 promoters by exogenously expressed or DNA repair.
A large body of evidence has pointed to the role forBRCA1 (Figures 7A and 7B). The p53-dependent en-
hancement of transcription by BRCA1 was completely BRCA1 in transcriptional control. The fusion of the car-
boxyl terminal domain of BRCA1 and the Gal4 DNA bind-and specifically abrogated by addition of the dominant-
negative mutant of BRG1 (Figures 7A and 7B). Taken ing domain activates transcription from Gal4-containing
promoters (Chapman and Verma, 1996; Monteiro et al.,together, these results demonstrate a functional associ-
ation of BRCA1 and a SWI/SNF-related complex. 1996). Moreover BRCA1 was shown to function as a
coactivator in a p53-mediated transcription (Ouchi et
al., 1998). More recently, an interaction between BRCA1Discussion
and CBP/p300 was reported (Pao et al., 2000). Identifica-
tion of BRCA1 as a component of the SWI/SNF complexThe novelty of this work lies in the following. First, it
provides a mechanism by which BRCA1 regulates tran-demonstrates the stable association of the BRCA1 pro-
scription through modulation of chromatin structure. In-tein with a SWI/SNF-related chromatin-remodeling com-
terestingly, the acidic transcriptional activation domainplex. Second, it demonstrates that BRCA1-containing
of BRCA1 was shown to induce chromosomal DNA repli-SWI/SNF complex is devoid of RNAPII, the components
cation and chromatin remodeling in yeast (Hu et al.,of the RAD50 complex, and BRCA2 and therefore does
1999). This may reflect the recruitment or stable associa-not represent a form of the RNAPII holoenzyme or the
tion of BRCA1 with one of the yeast SWI/SNF-relatedRAD50/Mre11/P95 complex. Third, it presents evidence
complexes by the acidic activation domain of BRCA1.for direct BRCA1±BRG1 interaction. Fourth, it shows
BRCA1 has also been implicated in DNA repair andthat the previously reported p53-mediated coactivation
transcription-coupled repair of oxidative DNA damagefunction of BRCA1 is mediated through the SWI/SNF
(Gowen et al., 1998; Moynahan et al., 1999; Scully et al.,complex. Fifth, it demonstrates the resolution of BRCA1-
1999). We envision two scenarios for the role of BRCA1-SWI/SNF to near homogeneity as a complex of some
SWI/SNF complex in DNA repair. First, this complex may18 polypeptides, including BRG1, BAF170, BAF155,
be required for activation of genes necessary for DNABAF60, and SNF5. The existence of a discrete BRCA1
damage response pathway. This is consistent with acomplex is thereby conclusively demonstrated and its
recent report indicating that ectopic expression ofstructure and mechanism of action are open to study.
BRCA1 resulted in induction of DNA damage responsePrevious studies presented evidence indicating the
genes such as KU70 and GADD45 (Harkin et al., 1999;association of BRCA1 and either RNAPII holoenzyme
(Scully et al., 1997a) or RAD50/Mre11/p95 (Zhong et al., MacLachlan et al., 2000). Second, it is possible that
Cell
262
Figure 6. BRCA1 Transcription Activity Is
Mediated through the SWI/SNF Complex
(A) Transient transfection assays showing the
stimulation of transcription by BRCA1 (5 mg).
The mutant BRCA1 (D11, 5 mg) did not have
any effect. (B) Transient transfection assays
showing the BRG1 dominant-negative mu-
tant (13, 0.5 mg) abrogates the BRCA1 stimu-
lation of transcription. The p53-G5B-CAT re-
porter was cotransfected into CEM cells with
the indicated plasmids. (C) Pu3R-CAT (3 mg)
or HIV-CAT (3 mg) was transfected with either
a TAX (1.5 mg) or TAT (1.5 mg) plasmids. Five
micrograms of dominant-negative mutant
was used in these assays. Transfection ex-
periments and CAT assays were performed
as described in Experimental Procedures.
The percent CAT conversion is given below
each lane.
BRCA1-SWI/SNF plays a direct role in homology- BRCA1 function and the biochemical pathways regu-
lated by BRCA1.directed DNA repair by allowing access to DNA repair
machinery via the chromatin remodeling activity of SWI/
Experimental ProceduresSNF. Further experiments using the purified BRCA1
complex in a defined DNA repair assay will be able to
Conventional Chromatographic Purificationresolve this question.
of the BRCA1 ComplexBRCA1 has also been implicated in maintaining ge-
Following cell breakage, nearly all BRCA1 is recovered in the soluble
netic stability through regulation of centrosome duplica- fraction. The BRCA1 complex was purified from 2 g of HeLa nuclear
tion and G2±M checkpoint (Xu et al., 1999). It is unlikely extract (Figure 2A). Nuclear extract was loaded on a 250 ml column
that BRCA1-SWI/SNF complex performs a direct role in of phosphocellulose (P11, Whatman) and fractionated stepwise by
centrosome duplication or checkpoint control, as these the indicated KCl concentrations in buffer A (20 mM Tris-HCl, pH
7.9, 0.2 mM EDTA, 10 mM bME, 10% glycerol, 0.2 mM PMSF). Theprocesses are not directly linked to functions requiring
P11 0.5 M KCl fraction (250 mg) was loaded on a 45 ml DEAE-chromatin modulation. A more likely scenario is the
Sephacel column (Pharmacia) and eluted with 0.35 M KCl. The 0.35involvement of the BRCA1 complex in the regulation of
M KCl elution (140 mg) was dialyzed to 700 mM NH4SO4 in buffertranscription of genes required for these processes. This
HB (20 mM HEPES, pH 7.6, 4 mM dithiothreitol, 0.5 mM EDTA, 10%hypothesis is supported by a recent report indicating
glycerol, 0.5 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and
the induction of cell cycle regulatory genes, such as 1 mg/ml pepstatin) and loaded on a Phenyl Superose HR 10/10. The
cdk4 and p21, following BRCA1 overexpression (Mac- column was resolved using a linear 10 column volume gradient of
Lachlan et al., 2000). 700 to 0 mM NH4SO4 in buffer HB. BRCA1 containing fractions were
Mutations in SNF5, another subunit of the SWI/SNF dialyzed to 10 mM KxPO4 in buffer HA (5 mM HEPES, pH 7.6, 1 mM
dithiothreitol, 0.5 mM PMSF, 10 mM CaCl2, 10% glycerol, 40 mMcomplex, have been shown to result in aggressive pedi-
KCl, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin)atric cancer (Versteege et al., 1998). In addition, alter-
and loaded on a BioScale CHT5-I column (BioRad). The column wasations in enzymes responsible for histone modifications
resolved using a linear 15 column volume gradient of 10 to 600 mMsuch as acteylteransferases and deactylases have also
KxPO4 in buffer HA. Fractions containing BRCA1 were dialyzed tobeen implicated in the development of malignancies
100 mM KCl in buffer A containing 1 mg/ml aprotinin, leupeptin, and
(Wolffe, 1999). Our finding that BRCA1 is a component pepstatin, and loaded on Mono Q HR 5/5 (Pharmacia). The column
of a chromatin remodeling complex not only extends was resolved using a linear 10 column volume gradient of 100 to
these findings by implicating chromatin remodeling 500 mM KCl in buffer A containing 1 mg/ml aprotinin, leupeptin,
complexes in the pathogenesis of breast and ovarian and pepstatin. BRCA1-containing fractions were fractionated on a
Superose 6 HR 10/30 (Pharmacia) equilibrated in 0.7 M KCl in buffercancers, but also provides a mechanistic insight into
BRCA1 Is a Component of a Chromatin Remodeling Complex
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Figure 7. Analysis of Endogenous p53 Re-
sponsive Promoters
(A) Multiprobe ribonuclease protection assay.
Samples of total RNA after the indicated
transfections were analyzed for the indicated
mRNA species as described in Experimental
Procedures. The protected fragment for each
mRNA is smaller than the probe size (e.g.,
p53 probe 312 nt, protected 283 nt). Lane
1 represents the probe set not treated with
RNase. L32 and GAPDH represent cyto-
plasmic and nuclear RNA controls for each
lane, respectively. Lanes 10 and 11 represent
the controls of HeLa RNA and yeast tRNA,
respectively.
(B) Quantification of fold induction of bclx,
p53, and p21 mRNA in (A) after transfection
with the indicated constructs.
A containing 0.1% NP-40, and 1 mg/ml aprotinin, leupeptin, and Mass Spectrometric Peptide Sequencing
Excised bands were subjected to in gel reduction, carboxyamido-pepstatin.
methylation, and tryptic digestion (Promega). Multiple peptide se-
quences were determined in a single run by microcapillary reverse-
Immunoaffinity Purification of BRCA1 Complex
phase chromatography (a custom New Objective 50 mm column
HeLa nuclear extract (1.2 g) was fractionated according to the proto-
terminating in a nanospray 15 mm tip) directly coupled to a Finnigan
col described above using P11 and DEAE-Sephacel columns. The
LCQ Deca quadrupole ion trap mass spectrometer. The ion trap
DEAE-Sephacel pool was then dialyzed to 150 mM KCl in buffer D
was programmed to acquire successive sets of three scan modes
(20 mM HEPES, pH 7.9, 0.25 mM EDTA, 20% glycerol, and 0.1%
consisting of: full scan MS over alternating ranges of 395±800 m/z
Tween 20). C20 antibodies (300±500 mg, Santa Cruz) were cross-
or 800±1300 m/z, followed by two data-dependent scans on the
linked to Protein A-Sepharose (1 ml, Repligen) using standard tech-
most abundant ion in those full scans. These dependent scans
niques (Harlow and Lane, 1988) for affinity purification of BRCA1
allowed the automatic acquisition of a high-resolution (zoom) scan
complex. The fractionated nuclear extract (DEAE-Sephacel, 10 mg)
to determine charge state and exact mass, and MS/MS spectra for
was incubated with 1 ml of antibody-Protein A beads for 4±5 hr in
peptide sequence information. MS/MS spectra were acquired with
buffer D at 48C. The beads were washed twice with 1 M KCl in buffer
a relative collision energy of 30%, an isolation width of 2.5 Da and
D followed by two washes with 100 mM KCl in buffer D. The proteins
dynamic exclusion of ions from repeat analysis. Interpretation of the
were eluted with either 0.1 M glycine, pH 2.5, and neutralized with
resulting MS/MS spectra of the peptides was facilitated by programs
1/10 volume 1.0 M Tris-HCl, pH 8.0, or overnight incubation with
developed in the Harvard Microchemistry Facility (Chittum et al.,
C20 peptide (4 mg/ml; corresponding to the last 20 amino acids of
1998) and by database correlation with the algorithm SEQUEST (Eng
BRCA1) in buffer D.
et al., 1994).
Affinity Purification of Human SWI/SNF Complex(es)
HeLa S3 cells expressing Flag-tagged SNF5 (Ini-1-11) were used Mononucleosome DNase I Cleavage Assay
Assay of ATP-dependent disruption of mononucleosomes was per-for the affinity purification of hSWI/SNF as described (Sif et al.,
1998). formed as previously described (Owen-Hughes et al., 1996).
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Immunoblot Analysis RNase Protection
Cells (293) were grown to mid-log phase and transfected at 2.5 3Anti-BRG1, BAF170, BAF155, BAF60b, SNF5 antibodies were de-
scribed (Wang et al., 1996a). Immunoblotting with alkaline phospha- 106 cells/10 cm plate. Five micrograms of each DNA was mixed with
ddH2O in a final volume of 450 ml. Fifty microliters of 2.5 M CaCl2tase was performed as described (Bochar et al., 2000).
was added to the mixture. Five hundred microliters of 23 HEPES
(pH 7.16) was added drop-wise to the solution. After incubation atIn Vitro Transcription
room temperature for 15 min, the solution was distributed evenlyTranscription was reconstituted as described (Bochar et al., 1999).
over the cells. After 4 hr at 378C, media was replaced by complete
DMEM. Cells were harvested 24 hr later.
Purification of Baculovirus Expressed Recombinant Proteins Twenty-four hours after transfection, RNA was isolated with
and Protein±Protein Interaction Studies RNAzol reagent (TEL-TEST, Inc.). 1.5 ml of RNAzol was used for
Recombinant proteins (rBAF155B, rBAF170, rFlag-SNF5, rFlag- each transfected plate. Samples (300 ml) were chloroform extracted
BRG1, and rHis-BRCA1) were expressed in a baculovirus expression and RNA was precipitated with an equal volume of isopropanol.
system. Insect cells (Sf21) were infected with one recombinant virus Pellets were washed with 70% ethanol and suspended in DEPC-
(rFlag-BRG1 or rHis-BRCA1) or coinfected with multiple viruses treated water at a final concentration of 5 mg/ml.
(rBAF155B, rBAF170, and rFlag-SNF5.) The infected cells (10 multi- RNase protection assays were performed using the hStress-1
plicity of infection and 48 hr post infection) were harvested and multiprobe template set of the RiboQuant Multi-Probe RPA kit (Phar-
sonicated in 100 mM KCl in buffer A. The cell lysates were cleared Mingen). Labeled RNA probes were generated using T7 polymerase
by centrifugation (20,000 3 g for 20 min at 48C.). The Flag-tagged and [a-32P] UTP. Fifteen micrograms of cellular RNA samples, 5
proteins (rFlag-BRG1 or rFlag-SNF5/rBAF155B/rBAF170 protein mg of HeLa control RNA, or 10 mg of yeast tRNA were separately
complex) were affinity purified with Anti-Flag M2 affinity gel (SIGMA) hybridized with labeled RNA probes. The mixture was incubated
according to the manufacturer's protocol except that buffer A with at 958C and cooled gradually to 568C overnight. The incubation
100 mM KCl, 300 mM KCl, and 100 mg Flag peptide in 100 mM KCl temperature was further decreased to 378C over 30 min prior to
was used in the binding, washing, and elution steps, respectively. RNase digestion. RNase A (19.2 ng) and RNase T1 (60 units) were
rHis-BRCA1 was purified using Ni-NTA Agarose (Qiagen) as recom- added to each sample and incubated at 308C for 45 min. After
mended by the manufacturer except that 500 mM KCl in buffer A termination of RNase digestion, RNA was precipitated and sus-
without EDTA was used. pended in 5 ml of loading buffer. Samples were run a 6% TBE/Urea
Protein±protein interactions were detected using an affinity- gel (Novex, Inc.) at 100 W. Dried gels were exposed to a Phosphoro-
bound Flag-tagged protein or protein complex. A target protein or Imager cassette (Molecular Dynamics) overnight. Ratios of L32 and
protein complex in 100 mM KCl in buffer A was added to the anti- GAPDH RNA controls from different samples were compared to
Flag M2 affinity gel bound protein or protein complex and allowed 293 mock sample. Counts obtained from protected fragments were
to interact with the gel-bound protein for 1 hr at 48C with constant divided by the ratios (L32 1 GAPDH) to get corrected values.
inversion. Nonspecifically bound proteins were removed by re-
peated wash with 300 mM KCl in buffer A. Bound proteins were
Acknowledgmentseluted with 100 mg Flag peptide in 100 mM KCl in buffer A and
analyzed by Western blotting using the indicated antibodies.
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mg/ml leupeptin, and 1 mg/ml pepstatin). The cell lysates were
cleared by centrifugation (105,000 3 g for 60 min at 48C). Concentra-
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